CeGaT enables verification of vaccination effectiveness through the Corona antibody test.

CeGaT’s CE-certified Corona antibody test can be used to determine the effectiveness of vaccination against SARS-CoV-2.

The now-approved vaccines against the SARS-CoV-2 coronavirus cause the body to form specific antibodies against the spike protein of SARS-CoV-2. If the vaccination is effective, this leads to a clearly measurable increase in the blood’s so-called IgG antibodies. Individuals who have formed these specific antibodies against SARS-CoV-2 are considered to be immune. CeGaT’s corona antibody test detects whether a person has created IgG antibodies and thus has acquired vaccination protection.


A significant increase in IgG antibodies in the blood is required for successful vaccination protection. To check the vaccination’s effectiveness, CeGaT, therefore, recommends that the Corona antibody test be performed no earlier than 7 days after the 2nd vaccination date.

The blood sample (serum) required for laboratory analysis can either be obtained free of charge at the CeGaT premises or by a medical doctor.

1. the CeGaT blood sampling site can be visited without an appointment Monday through Friday from 1:00 pm to 5:00 pm, and Saturday from 9:00 am to 1:00 pm. Blood collection is performed free of charge on-site by CeGaT’s medical staff.

2. Alternatively, the respective family doctor can perform the blood collection. The collection tubes required to achieve the blood collection can be ordered free of charge via the CeGaT web portal. Other blood collection tubes cannot be accepted for technical reasons. The collected sample can then either be sent to CeGaT by mail or handed in on-site.

CeGaT performs the testing for IgG antibodies in its in-house laboratory and sends the results within 1-3 days after receiving the sample. The laboratory is accredited according to CAP/CLIA and DIN EN ISO 15189 and thus meets the highest international quality standards.

The CeGaT blood collection kit contains:

  • CeGaT tubes for carrying out the blood collection procedure
  • all materials needed for the return shipment of the sample

PRICE EUR 25,- per sample sent in

The specificity of the Corona antibody test:

The antibody test used by CeGaT is CE certified and approved by the FDA (Food and Drug Administration, USA). Several independent scientific comparative studies have confirmed the reliability of EUROIMMUN’s ELISA test and determined a specificity of 99.6 percent and a sensitivity of 94.4 percent. Thus, the Corona antibody test performed by CeGaT guarantees the highest quality for the evaluation of vaccination effectiveness.

More information on the Corona antibody test can be read here.

Update of CeGaT Exome Xtra Increases Solution Rate of Complex Patient Cases

Based on the latest scientific findings, CeGaT has optimized its whole-exome diagnostics, further increasing the solution rate of complex patient cases. Since the update, CeGaT Exome Xtra offers optional pharmacogenetic testing. The medical report will then also provide information on personal drug efficacy, enabling individualized medication.

One year ago, CeGaT launched CeGaT Exome Xtra, the most effective genetic test for patients with complex, non-specific, and rare diseases. CeGaT Exome Xtra combines all genetic diagnostics achievements in one test and solves more patient cases than commercially available whole-exome sequencing (WES) and whole-genome sequencing. Regular updates ensure that CeGaT Exome Xtra is always in line with the latest genetics research to increase the diagnostic yield.

20 percent more intronic variants covered

Unlike standard WES, CeGaT Exome Xtra considers all known disease-causing regions of the complete genome, including relevant intronic variants. In the update, the new relevant variants of the HGMD and ClinVar databases were also added to CeGaT Exome Xtra. The number of intronic variants covered was thus increased by more than 20 percent to almost 22,000 variants. CeGaT Exome Xtra thus still covers all regions of the genome described as disease-relevant in HGMD and ClinVar.

By including intronic variants, CeGaT Exome Xtra sets itself apart from commercially available exome enrichments. It is not limited to coding regions, but includes all disease-causing non-coding variants and also covers individual transcripts or cryptic exons.

Pharmacogenetic testing helps in drug selection and dosage

Pharmacogenetics takes into account that all people metabolize drugs in different ways: A drug that is beneficial to one person remains ineffective or may even cause harm in another. With this update, CeGaT Exome Xtra offers the option of pharmacogenetic testing. Exome Xtra data is used to classify about 80 active ingredients as to whether they are degraded quickly or slowly in the individual. Based on this information, physicians can select the most suitable drug and administer it in the correct dosage.

Continuous consideration of scientific progress

CeGaT Exome Xtra is designed to generate the most comprehensive sequencing data and provide an unmatched foundation for the best genetic diagnostics on the market. Knowledge of genetic diseases is expanding rapidly; new genomic regions of clinical relevance are identified every year. To reflect this progress, CeGaT continuously reviews and revises its genetic diagnostics. The diagnostic panels underlying CeGaT Exome Xtra are constantly updated in close collaboration with medical experts and using the latest literature.

With CeGaT Exome Xtra, patients and treating physicians benefit from a unique approach that combines the advantages of Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) while avoiding their disadvantages. Thereby, CeGaT Exome Xtra achieves better results than commercially available WES and WGS and dramatically increases diagnostic yield. More information can be found here.

CeGaT Enables Self-Swabs for COVID-19 – High-Quality qPCR test, No Rapid Test

To simplify access to corona testing and reduce waiting times at corona testing stations, CeGaT GmbH now offers kits for self-swabs for COVID-19. With the help of the CeGaT collection kit, the nasopharyngeal swab for acute corona diagnostics can be performed on one`s own. CeGaT thus opens up another possibility for rapid and uncomplicated testing for infection with the SARS-CoV-2 virus.


The swab kits can be ordered via the homepage at https://www.cegat.de/en/diagnostics/corona-diagnostics/corona-kit/ or personally picked up at the CeGaT premises during the test station’s opening hours.

The swab can be performed on any day and at home. Detailed instructions are provided, and an explanatory video can also be found at https://www.cegat.de/en/diagnostics/corona-diagnostics/corona-kit/. The sample can then be sent by mail to CeGaT or handed in on-site. The nasopharyngeal swab is analyzed for viral RNA in CeGaT’s laboratory using real-time polymerase chain reaction (RT-PCR). With the aid of this highly sensitive method, CeGaT is able to detect the smallest amounts of the virus and identify infection at an early stage.

The medical reports are prepared in German and English and can be accessed the following day via a secure portal on CeGaT’s homepage. All findings are also sent by mail. If a copy of the passport is enclosed with the sample, the passport number is also listed on the report.

CeGaT- collection kit contains:

  • All materials for performing the swab
  • Instructions for correct collection of the specimen
  • All materials needed for the return shipment of the sample

Price EUR 65,- per sample sent in

Further information about the self-swab

CeGaT Tests for Active Corona Infections

Since October 1, anyone who would like to (or has to) be tested for active corona infections can come to CeGaT’s premises without prior appointment. The result is available within 24 hours and can be downloaded via a secure system. For companies and larger groups, CeGaT offers a mobile service for taking nasopharyngeal swabs.

In addition, blood collection for the antibody test is offered again from October 1.

Opening hours are Mon-Fri 1.00 p.m. to 5 p.m., Sat 9.00 a.m. to 1.00 p.m.

For further questions, please contact our team at corona@cegat.de or by phone at 0049 7071 565 44 20.

Coronavirus Test

The test determines whether a person is infected with SARS-CoV-2 at the time of swab collection. A combined nose-and-throat (nasopharyngeal) swab is examined for viral RNA by real-time polymerase chain reaction (RT-PCR). Smallest amounts of the virus can be detected, and an infection can be diagnosed at an early stage.

  • Test for active infection with SARS-CoV-2
  • Price EUR 65,- per sample (self-pay, not covered by medical insurance)
  • Required sample material: Nasopharyngeal swab.
  • CeGaT carries out the swab collection on its property in Tübingen from October 1: Mon-Fri 1.00 p.m. to 5 p.m., Sat 9.00 a.m. to 1.00 p.m. Registration is neither necessary nor possible.
  • The result is available within 24 hours and can be viewed in a secure portal. Positive results are immediately communicated by telephone and – according to the respective regulations – reported to the public health department.

Corona Antibody Test

This test determines whether a person has antibodies against the novel coronavirus or not. People with antibodies can be assumed to have undergone a corona infection.

  • CE-marked test for antibodies against the S1 domain of the spike protein of SARS-CoV-2
  • Price EUR 25,- per sample (self-pay, not covered by medical insurance)
  • Required sample material: blood (serum)
  • CeGaT carries out the blood collection on its premises in Tübingen from October 1: Mon-Fri from 1:00 p.m. to 5:00 p.m., Sat from 9:00 a.m. to 1:00 p.m. Registration is neither necessary nor possible. Blood collection is also possible in medical practices with the sample tubes ordered from CeGaT. Please consult your family doctor about this. Important: In this case, the CeGaT sample tubes must be ordered via https://www.cegat.de/en/diagnostics/corona-antibody-test/


Update and Extension of the Panel for Genetic Eye Diseases

CeGaT has updated and expanded the Diagnostic Panel for Genetic Eye Diseases. As part of the regular updates, the panel was revised according to the current scientific knowledge, thereby increasing its diagnostic sensitivity.

In addition, new gene sets have been added to the panel, which can now also be used for precise diagnoses of the following hereditary eye diseases:

Congenital nystagmus, X-linked

Congenital nystagmus is characterized by congenital, uncontrolled movements of the eyes, which are also described as jerking or trembling. Eye movement disorders vary greatly in frequency, amplitude, and shape (e.g., pendulum nystagmus) and are sometimes accompanied by visual impairment and disturbances. The X-linked nystagmus usually occurs in the first half-year of life and results from changes in the genes FRMD7 and GPR143.

Progressive external ophthalmoplegia

Progressive external ophthalmoplegia manifests in progressive paralysis of the external eye muscles, which severely limits the movement of the eyes. Since eyelid muscles can also be affected, a common sign of the disease is the drooping of one or both eyelids (ptosis). The cause are mitochondriopathies, which are caused by a malfunction or damage to the mitochondria.

Congenital cranial dysinnervation syndromes

Congenital cranial dysinnervation syndromes (CCDDs) are a subgroup of incomitant strabismus. It describes strabismus syndromes in which the degree of strabismus depends on the direction of gaze. It is characterized by a non-progressive disturbance of the eye movement (oculomotor function), in some cases accompanied by upper eyelid ptosis, i.e. the drooping of an eyelid. The syndromes are caused by diseases or maldevelopments of eye muscles or eye cavities (orbital diseases) or cranial nerves (cranial nerve paresis). They cause a defective innervation of the muscles.

All CeGaT panels are examined with CeGaT’s large panel approach. We always sequence all genes of a panel and evaluate the requested gene set. If necessary, we can quickly extend the evaluation to other gene sets. This gives you access to the most flexible and cost-efficient differential diagnostics. In addition, we offer a screening of all differential diagnostic relevant genes of the panel for variants of ACMG classes 4 and 5. CeGaT’s panel diagnostics also include the free of charge regular re-evaluation of variants of uncertain clinical significance (VUS) to increase the diagnostic yield further.

We are convinced that all patients should receive the best possible diagnostics. For this reason, our panels routinely examine single nucleotide variation (SNVs) and copy number variants (CNVs) and check for mosaicism. If necessary, we validate pathogenic deletions or duplications using MLPA or qPCR before reporting. The highest quality is our standard.

For further information on the panels, please contact us at sales@cegat.com. The new panel can be ordered here.